ARCA Logo - JPEG.jpg
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 10, 2018 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
May 08, 2018 16:15 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Cardiometabolic Health Congress (CMHC) Concludes CMHC West 2018
May 08, 2018 10:25 ET | Cardiometabolic Health Congress
Boca Raton, May 08, 2018 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress concluded its event CMHC West: Advancing Cardiometabolic Health from East to West on Saturday, May 5th at Wynn Las Vegas....
ARCA Logo - JPEG.jpg
ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
April 23, 2018 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Amarin_Logo_JPEG.jpg
Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
March 01, 2018 05:00 ET | Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, March 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
February 26, 2018 08:00 ET | ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro...
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
November 16, 2017 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Earth Science Tech, Inc. Announces Partnership with Bionatus to Help Manufacture, Distribute, & Continue Further R&D on Cannabis (CBD) Products
August 22, 2017 08:25 ET | Earth Science Tech, Inc.
Hollywood, FL, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
August 16, 2017 08:30 ET | ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
August 09, 2017 16:30 ET | ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...